<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: EndoTAG-1 (ET), a novel formulation of cationic liposomes carrying embedded paclitaxel (<z:chebi fb="6" ids="45863">Taxol</z:chebi>), shows antitumoral activity, targeting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> endothelial cells in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with advanced <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> were evaluated investigating effects on pharmacokinetics and <z:e sem="disease" ids="C1658953" disease_type="Neoplastic Process" abbrv="">tumor vasculature</z:e> using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and contrast-enhanced ultrasound (CEUS) </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: The pharmacokinetic (PK) profile of ET (22 mg/m(2) i.v.) was evaluated after single and repeated doses </plain></SENT>
<SENT sid="3" pm="."><plain>DCE-MRI and CEUS explored <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> before, during and after the 4-week treatment cycle </plain></SENT>
<SENT sid="4" pm="."><plain>Angiogenic biomarkers were assessed </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> response was evaluated by modified RECIST </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The PK profile demonstrated slight accumulation of paclitaxel after repeated doses </plain></SENT>
<SENT sid="7" pm="."><plain>DCE-MRI parameters K(trans) and/or iAUC(60) showed a trend to decrease </plain></SENT>
<SENT sid="8" pm="."><plain>Changes of blood flow-dependent parameters of DCE-MRI and CEUS were well correlated </plain></SENT>
<SENT sid="9" pm="."><plain>Angiogenic biomarkers revealed no clear trend </plain></SENT>
<SENT sid="10" pm="."><plain>ET was generally well tolerated; common toxic effects were <z:mp ids='MP_0002899'>fatigue</z:mp> and hypersensitivity reactions </plain></SENT>
<SENT sid="11" pm="."><plain>Nine (9 of 18) patients had stable disease after the first treatment cycle </plain></SENT>
<SENT sid="12" pm="."><plain>Four patients without disease progression continued treatment </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: This study including multiple pretreated patients with different <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> revealed individually distinctive hemodynamic alterations by DCE-MRI </plain></SENT>
<SENT sid="14" pm="."><plain>The PK profiles of ET were similar as observed previously </plain></SENT>
</text></document>